LobbyingCrysalis Biosciences lobbying by quarter
Crysalis Biosciences's latest lobbying report covers Q2 2025, at under $5,000. Its first report covers Q4 2024; the issues it reports most are Energy/Nuclear.
Crysalis Biosciences
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2024 | $10K | 1 |
| Q1 2025 | $30K | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Energy and nuclear$40K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| Holland & Knight | $40K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 25/07/08for Q2 2025 | Holland & Knight | Under $5,000 |
| 25/04/08for Q1 2025 | Holland & Knight | $30K |
| 25/01/19for Q4 2024 | Holland & Knight | $10K |
| 24/12/31for Q4 2024 | Holland & Knight | Under $5,000 |